The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

There is a surprising number of products that come with into your home with stubborn stickers. A lot of stores still use price stickers, for instance, and glassware almost always has a sticker ...

3M (NYSE: MMM) recently reported its Q4’24 results, with revenues and earnings beating the street estimates. The company reported adjusted revenue of $5.81 billion and earnings of $1.68 on a per ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...

they are likely to miss some of the important instructions to be announced in the examination rooms/ halls. The NTA will not be responsible for any delay of the candidate to reach the examination ...

Shares of industrial conglomerate 3M (NYSE:MMM) jumped 6.1% in the pre-market session after the company reported fourth-quarter results, which exceeded analysts' revenue and EPS expectations.

(Reuters) -3M Co forecast profit growth for 2025 and beat fourth-quarter estimates as the U.S. industrial conglomerate benefited from efforts to revive sales and reduce costs, sending its shares ...

3M's end markets remain mixed, but management has a margin expansion opportunity. CEO Bill Brown will outline his vision for the company in February. The stock looks like a good value and is a ...